Research Article
Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control
Table 3
EWOC with Covariate. Design operating characteristic with respect to safety and efficiency of the trial.
| | 0.2 | 0.4 | 0.6 | 0.8 |
| Proportion of DLTs | 0.3337 | 0.2721 | 0.2183 | 0.1759 | Proportion of DLTs in group A | 0.3319 | 0.2751 | 0.2222 | 0.1764 | Proportion of DLTs in group B | 0.3356 | 0.2691 | 0.2143 | 0.1754 | Proportion overdosed in group A | 0.3361 | 0.1790 | 0.04995 | 0.0008 | Proportion overdosed in group B | 0.3346 | 0.1802 | 0.0497 | 0.0010 | Bias () | −0.0134 | −0.0387 | −0.0965 | −0.2002 | MSE () | 0.0716 | 0.1373 | 0.2142 | 0.3425 |
|
|